Patent Issued for Pharmaceutical compositions comprising sepiapterin and uses thereof (USPTO 11752154).

A patent has been issued for pharmaceutical compositions containing sepiapterin and their use in the treatment of tetrahydrobiopterin-related disorders. Sepiapterin is an essential cofactor for various enzymes involved in neurotransmitter synthesis. The compositions are stable at room temperature for at least 6 months and can be formulated as solid compositions or suspensions. The patent also includes the use of an antioxidant to stabilize the sepiapterin in the composition. This invention provides a potential new therapy for tetrahydrobiopterin deficiency. [Extracted from the article]